Healthcare Industry News: HSMN NewsFeed
News Release - March 29, 2019
PolarityTE Announces Richard Hague, Formerly from Sanofi, Genzyme and Recently Anika Therapeutics as Chief Operating OfficerCurrent Chief Operating Officer, Ned Swanson M.D., Continues on as Chief Translational Medicine Officer
SALT LAKE CITY, March 29, 2019 -- (Healthcare Sales & Marketing Network) -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that Richard Hague will join as the Company's Chief Operating Officer on April 8, 2019. Mr. Hague brings to PolarityTE experience in many aspects of corporate development and operations from his more than 30-year career in the biotechnology industry, including launching a variety of autologous cell and tissue therapies. Current COO Ned Swanson, MD, will continue on as PolarityTE's Chief Translational Medicine Officer.
Mr. Hague joins PolarityTE from Anika Therapeutics where he served as Chief Commercial Officer, overseeing the launch of a novel device-drug combination injection therapy for osteoarthritis. Prior to his tenure with Anika, Mr. Hague served as Vice President of Sales and Marketing at TEI Medical, which was later acquired by Integra. While at TEI Medical, he built a commercial team for a bioengineered dermal scaffold used in the treatment of wounds. Mr. Hague spent a significant portion of his career at Genzyme and later Sanofi (post Sanofi's acquisition of Genzyme). While at Sanofi, he oversaw all of Sanofi Biosurgery's U.S. Cell Therapy and Regenerative Medicine commercial activities, including cell therapies Carticel, MACI and Epicel.
"With Richard's 30 years of experience in the commercialization and operations of complex cell and tissue therapies, I have no doubt he will bring incredible value to our technologies, products, team and ultimately to the patients that we serve. Bringing Richard into the executive team allows Dr. Ned Swanson to focus on his true passion, which is translational medicine and clinical research," said Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE.
"I am pleased to join the passionate and determined PolarityTE team and look forward to helping them change the landscape and expectations for cell and tissue based therapies and regenerative medicine. Their platform technology holds promise and potential like nothing else that I have seen in my career. PolarityTE is uniquely driven by doctors who left clinical practice with the steadfast goal of delivering a different type of product and result to providers and patients, and I am motivated to help see this goal to completion," said Richard Hague, Chief Operating Officer of PolarityTE.
About Richard Hague
Richard Hague is an experienced executive in the biotechnology and life sciences fields. He has primarily been focused on commercialization of cell therapy solutions in the orthopedic and wound care markets. His areas of expertise include general management, cross functional leadership, global sales and marketing, new product launch, strategic planning and execution, organizational effectiveness, and build out and management of multi-channel sales models. He has worked in various therapeutic areas including cell therapy, regenerative medicine, biologics, orthopedics, sport medicine, combination drug/device, pain management and wound care. Mr. Hague has worked for Genzyme Biosurgery, Sanofi, TEI Medical and Anika Therapeutics. He has a Bachelor of Science in Marketing from the University of Connecticut.
PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient's own tissue and uses the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.
Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).
POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.